IM Cannabis Corp. IMCC and Avant Brands have forged a significant international trademark licensing agreement, aiming to introduce Avant’s BLK MKT brand into Germany’s cannabis market. This strategic move is set to bolster both companies’ positions in the industry, tapping into a promising frontier for growth.
Cultivating Market Presence
The primary goal of this alliance is to empower IM Cannabis’ subsidiary in Germany, Adjupharm GmbH, with exclusive rights to launch the BLK MKT brand in Germany’s medical cannabis sector. Germany’s recent legalization of medical cannabis makes this agreement well-timed, aligning with the nation’s increasing acceptance and demand for premium cannabis products.
This licensing arrangement underscores IM Cannabis’ dedication to implementing a high-end strategy in Germany, complementing its existing ventures in Israel. The collaboration not only solidifies Avant’s position in the ultra-premium segment but also strengthens IM Cannabis’ capacity to provide top-tier cannabis offerings to the German market.
Impacts on the Market
IM Cannabis and Avant are both hopeful about the positive outcomes that this partnership is expected to deliver. By leveraging Avant’s premium cannabis products and IM Cannabis’ robust sales, marketing, and distribution capabilities, the companies are poised to meet the growing demand in Germany.
IM Cannabis anticipates that this collaboration will streamline the supply chain and bring quality brands to the German market. Avant, on the other hand, highlights the agreement’s importance in their enduring partnership with IM Cannabis.
Avant’s possession of ICANN-GAP and GACP certifications positions it favorably for international cannabis distribution.
Thriving Cannabis Market Landscape
A report from Mordor Intelligence forecasts that the global cannabis market, valued at $33.84 billion in 2024, is projected to reach $69.25 billion by 2029, growing at a CAGR of 15.40%. This expansion is being fueled by the increasing acceptance of cannabis for medicinal purposes and the rise in recreational use driven by global legalization efforts. North America, especially the United States, is at the forefront of this growth, with significant advancements in medicinal cannabis adoption. The trend of legalization in countries like Australia, Canada, Germany, and Thailand points to a promising future for the industry, driven by the growing acknowledgement of cannabis’s therapeutic benefits.
Stock Performance and Recognition
In the past year, IMCC shares have surged by 24.2%, outpacing the industry’s 2.8% growth rate.
Zacks Rank and Financial Insights
IM Cannabis currently holds a Zacks Rank #4 (Sell).
Other promising stocks in the broader medical space include DaVita DVA, Stryker SYK, and Cardinal Health CAH, with DaVita boasting a Zacks Rank #1 (Strong Buy) and Stryker and Cardinal Health carrying a Zacks Rank #2 (Buy) each at present. Recent estimations suggest positive momentum for DaVita, with a surge of 63.8% in the past year.
Stryker’s shares have seen an upward trend, rising by 20.8% in the past year. The company has consistently surpassed earnings estimates in the last four quarters, showcasing steady growth. Similarly, Cardinal Health’s stock has surged by 39% in the past year, with strong earnings surprises quarter after quarter.
While the market presents exciting prospects and flourishing alliances, only time will reveal how these developments shape the cannabis landscape in Germany and beyond.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3%, and +673.0%.
Today, See These 5 Potential Home Runs >>
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
